ImmunityBio To Present Data From Multiple Clinical Trials at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
ImmunityBio, Inc. (NASDAQ: IBRX) announced that data from its QUILT 3.032 trial for BCG-unresponsive non-muscle invasive bladder cancer will be presented at the ASCO Annual Meeting, taking place from June 3-7 in Chicago. Principal Investigator Karim Chamie, M.D., will share final clinical results of the pivotal trial involving the IL-15RαFc superagonist N-803 combined with BCG. Additionally, the QUILT 88 trial results showcasing improved survival rates in advanced pancreatic cancer patients will also be presented. ImmunityBio will exhibit at booth 26135.
- Acceptance of abstracts for presentation at a major oncology conference.
- Potentially significant results from pivotal trial QUILT 3.032 for IL-15RαFc superagonist N-803.
- QUILT 88 trial shows over double historical overall survival rates in pancreatic cancer.
- None.
- Data from ImmunityBio’s QUILT 3.032 BCG-unresponsive non-muscle invasive bladder cancer trial will be presented by principal investigator in an oral presentation
- Poster presentation of QUILT 88 pancreatic data
-
QUILT 3.032 Oral Presentation: Principal Investigator
Karim Chamie , M.D., Associate Professor of Urology atUCLA , will present final clinical results of pivotal trial of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive CIS and papillary non-muscle-invasive bladder cancer (NMIBC). - QUILT 88 Poster Session: Phase 2 clinical trial of DAMP inducers combined with IL15 superagonist, N-803, and anti–PD-L1 NK cell therapy more than doubles historical overall survival in patients with third- to sixth-line advanced pancreatic cancer.
About
ImmunityBio’s clinical pipeline consists of 26 actively recruiting clinical trials—17 of which are in Phase 2 or 3 development—across 13 indications in liquid and solid tumors (including bladder, pancreatic, and lung cancers) and infectious diseases (including SARS-CoV-2 and HIV). Anktiva™, ImmunityBio’s lead cytokine fusion protein, is a novel interleukin-15 (IL-15) superagonist complex and has received Breakthrough Therapy and Fast Track Designations from the
The company has established GMP manufacturing capacity at scale with cutting-edge cell manufacturing expertise and ready-to-scale facilities, as well as extensive and seasoned R&D, clinical trial, and regulatory operations, and development teams. For more information, please visit: www.immunitybio.com
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the information to be presented at the upcoming ASCO meeting, results of the Company’s clinical trials, the potential use and efficacy of ImmunityBio’s product candidates for various indications, and potential regulatory approval, commercialization and commercial success of ImmunityBio’s product candidates, among others. Statements in this press release that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as “anticipates,” “believes,” “continues,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. Statements of past performance, efforts, or results of our preclinical and clinical trials, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio’s management as well as assumptions made by and information currently available to
View source version on businesswire.com: https://www.businesswire.com/news/home/20220428005514/en/
Investors
844-696-5235, Option 5
Sarah.Singleton@immunitybio.com
Media
Greg Tenor
Salutem
+1 717-919-6794
Gregory.Tenor@salutemcomms.com
Source:
FAQ
What are the key results of ImmunityBio's QUILT 3.032 trial?
When is the ASCO Annual Meeting where ImmunityBio will present its data?
What are the findings from the QUILT 88 trial?
What is ImmunityBio's stock symbol?